Breaking News

AtheroNova Appoints COO

April 9, 2014

Johnson brings 25 years of experience

Randolph M. Johnson, Ph.D. has been appointed chief operating officer of AtheroNova Inc. Dr. Johnson has 25 years of experience in the pharma, biopharma, drug delivery and medical device industries in both start-ups and global companies. He also has experience in entrepreneurial financing, corporate funding alliances/joint ventures and IPO launches. His scientific experience is concentrated in the areas of cardiovascular disease, oncology, endocrinology, and neurology.
 
Most recently, Dr. Johnson served as the chief of technology development and vice president of research at KAI Pharmaceuticals, where he contributed to an equity exit and acquisition by Amgen in a $315 million transaction for Velcalcetide (AMG-416) to treat chronic kidney disease.
 
Previously, Dr. Johnson served as senior vice president of Research and Preclinical Development for Cellgate, providing R&D leadership in novel molecular transporters and polyamine analogs for hyperproliferative diseases. Dr. Johnson was a founding member at DURECT Corp., a drug delivery and medical device spin-out from Alza Corp, and held scientific leadership positions with Roche Bioscience, Syntex Research, and Genentech.
 
"We are pleased to announce that Dr. Johnson has joined AtheroNova's management team, bringing his talents and leadership to AtheroNova's efforts to develop our platform of systemically available bile acids for the treatment of cardiovascular disease," said Thomas W. Gardner, chief executive officer of AtheroNova. "Dr. Johnson is a seasoned pharmaceutical executive with strength in drug discovery, R&D and in the operational aspects of running companies in this industry. Everyone on the AtheroNova team is looking forward to Dr. Johnson's contributions to the Company's first-in-class compounds for atherosclerosis regression and lipid modulation technology."

blog comments powered by Disqus
  • Cold Chain Packaging Trends

    Cold Chain Packaging Trends

    Kristin Brooks, Contract Pharma||February 4, 2016
    Susan Li of UPS discusses supply chain trends, challenges, and packaging innovations

  • Packaging Equipment Trends Preview

    Packaging Equipment Trends Preview

    Kristin Brooks, Contract Pharma||January 26, 2016
    Christian Treitel of Bosch Packaging Technology discusses trends and capabilities

  • Tackling Drug Serialization Challenges

    Tackling Drug Serialization Challenges

    Tim Wright, editor||January 22, 2016
    Siemens and Adents together will develop a combined hardware plus software solution for pharma industry

  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016